The end to animal testing marks the beginning of better biomedicine
No longer will our medicines be gated through animals, but rather through entirely human systems — leading to breakthrough options for the humans that need them.
Related Articles
HIV protection with just two shots a year: FDA approves Gilead drug
A new twice-yearly shot could be a “game changer” in the fight against AIDS, but experts’ hopes have dimmed because of the current political climate.
Vinay Prasad named chief medical and science officer at FDA
Vinay Prasad is taking on several big roles at the FDA, solidifying his position as a top advisor to Commissioner Marty Makary.
Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access?
Gilead has won FDA approval for an HIV prevention shot that is administered only once every six months. When will low-income countries gain access?
U.K. decision blocks a pair of Alzheimer’s drugs from access through its national health service
A U.K. health agency said the Alzheimer’s drugs Kisunla and Leqembi are not cost-effective, meaning they won’t be offered through the NHS.
Why a lot of Native American deaths are not counted
Native American deaths are significantly undercounted because of errors in death certificates, a new study claims.
More universities open to private equity deals, and emerging companies turn to new targets
The latest from the BIO 2025 conference: more universities open to private equity deals, emerging companies turn to new targets, and more.
U.K. decision blocks a pair of Alzheimer’s drugs from access through its national health service
A U.K. health agency said the Alzheimer’s drugs Kisunla and Leqembi are not cost-effective, meaning they won’t be offered through the NHS.
Top gene therapy regulator forced out at FDA
Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug Administration, and her deputy Rachael Anatol have been
Top gene therapy regulator forced out at FDA
Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug Administration, and her deputy Rachael Anatol have been
Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access?
Gilead has won FDA approval for an HIV prevention shot that is administered only once every six months. When will low-income countries gain access?
